serine has been researched along with cefepime in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelraouf, K; Almarzoky Abuhussain, S; Nicolau, DP | 1 |
| Abdelraouf, K; Gill, CM; Nicolau, DP | 1 |
| Dowell, JA; Henkel, T; Marbury, TC; Smith, WB | 1 |
| Mensa, J; Soriano, A | 1 |
1 review(s) available for serine and cefepime
| Article | Year |
|---|---|
Mechanism of action of cefiderocol.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cattle; Cefepime; Cefiderocol; Ceftazidime; Cephalosporins; Gram-Negative Bacteria; Iron; Quinolones; Serine; Tetracyclines | 2022 |
3 other study(ies) available for serine and cefepime
| Article | Year |
|---|---|
In vivo pharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteria.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Borinic Acids; Carboxylic Acids; Cefepime; Cephalosporins; Humans; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Serine | 2020 |
In vivo activity of WCK 4282 (high-dose cefepime/tazobactam) against serine β-lactamase-producing Enterobacterales and Pseudomonas aeruginosa in the neutropenic murine thigh infection model.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Escherichia coli; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Serine; Tazobactam; Thigh | 2021 |
Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Borinic Acids; Carboxylic Acids; Cefepime; Humans; Renal Insufficiency; Serine | 2022 |